Back to search
FDAFDA · Food and drugs·Recall number D-1516-2014

Cataflam (diclofenac potassium) tablets, 50 mg, 100-count bottles, Rx only, Manufactured by: Patheon Inc., Whitby Operations, Ontario, Canada L1N 5Z5; Distributed by: Novartis Pharmaceuticals Corp., East Hanover, New Jersey 07936; NDC 0078-0436-05, UPC 3 0078-0436-05 2.

Published August 13, 2014 · Recall initiated: July 30, 2014

Summary

FDA records drug Class III recall D-1516-2014, published August 13, 2014 and initiated July 30, 2014. Recalling firm: Novartis Pharmaceuticals Corp.; Status: Terminated; Reported quantity: 50 bottles; Lot: Lot # PKTS, Exp 01/17. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsule Specifications: Ink identification had rubbed off tablets in transit making them illegible to pharmacists and consumers.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Novartis Pharmaceuticals Corp.
Distributor
Nationwide
Lot
Lot # PKTS, Exp 01/17
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cataflam (diclofenac potassium) tablets, 50 mg, 100-count bottles, Rx only, Manufactured by: Patheon Inc., Whitby Operations, Ontario, Canada L1N 5Z5; Distributed by: Novartis Pharmaceuticals Corp., East Hanover, New Jersey 07936; NDC 0078-0436-05, UPC 3 0078-0436-05 2. recalled?

Yes. FDA published recall D-1516-2014 on August 13, 2014. Reported hazard: Failed Tablet/Capsule Specifications: Ink identification had rubbed off tablets in transit making them illegible to pharmacists and consumers.

What should I do if I have this product?

Voluntary: Firm initiated · Letter